TD Cowen lowered the firm’s price target on BioNTech (BNTX) to $110 from $122 and keeps a Hold rating on the shares. The firm updated its model following Q4 results as all eyes are now on its oncology pipeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech price target raised to $143 from $130 at BMO Capital
- BioNTech’s 2024 Earnings Highlight Oncology Focus
- Cautious Outlook for BioNTech SE Amid Revenue Shortfall and Oncology Pipeline Uncertainty
- BioNTech price target lowered to $143 from $147 at BofA
- BNTX Earnings: BioNTech Stock Slips Despite Q4 Beats